General Information of the Drug (ID: M6APDG03964)
Name
DS-8895
Status
Phase 1
TTD Drug ID
D03YBJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ephrin type-A receptor 2 (EPHA2)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
References
Ref 1 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022 May 21;13(5):483. doi: 10.1038/s41419-022-04950-2.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).